Ishihara Yo, Nishiguchi Sho, Branch Joel, Tanaka Eri
General Internal Medicine, Shonan Kamakura General Hospital, Kanagawa, JPN.
General Internal Medicine, Yao Tokushukai General Hospital, Osaka, JPN.
Cureus. 2022 Jul 16;14(7):e26916. doi: 10.7759/cureus.26916. eCollection 2022 Jul.
A 74-year-old woman with type 2 diabetes mellitus presented with nausea and abdomen distension. Four days prior, liraglutide 0.6 mg had been commenced. An abdominal computed tomography scan revealed gastric dilatation without mechanical obstruction which clinically suggested gastroparesis (GP). Her symptoms resolved after liraglutide discontinuation. A gastroscopy revealed reflux esophagitis. Taken together, GP may have developed along with reflux esophagitis due to liraglutide administration. Liraglutide's action inhibits gastric motility. Physicians should be cognizant of the side effects of GLP-1 agonists even in low dose in patients who have gastric emptying symptoms suggesting GP.
一名74岁的2型糖尿病女性患者出现恶心和腹胀。四天前开始使用0.6毫克利拉鲁肽。腹部计算机断层扫描显示胃扩张但无机械性梗阻，临床提示胃轻瘫（GP）。停用利拉鲁肽后她的症状缓解。胃镜检查显示反流性食管炎。综合来看，使用利拉鲁肽可能导致了胃轻瘫和反流性食管炎同时发生。利拉鲁肽的作用会抑制胃动力。即使是低剂量使用GLP-1激动剂，医生也应该意识到其在有提示胃轻瘫的胃排空症状的患者中可能产生的副作用。
